Bristol-myers Squibb Compnay

Bristol-myers Company

Osamu Tenmyo

Masataka Konishi

Takeo Miyaki

Mitsuaki Tsunakawa

Toshikazu Oki

Koji Tomita

Masahisa Oka

Hiroshi Kawaguchi

Tetsuro Yamasaki

Nobuaki Naruse

Hiroaki Ohkuma

Satoshi Yamamoto

Yosuke Sawada

Soichiro Toda

Takashi Tsuno

Masaru Sugawara

Mary P Rosser

Toshifumi Hasegawa

Noriyuki Ohkusa

A novel antibiotic complex designated BU-4224V produced by fermentation of Kibdelosporangium albatum sp. nov. Strain R761-7. The complex may be separated chromatographically into bioactive components designated BU-4224V A, B.sub.1, B.sub.2, and C. The components BU-4224V B.sub.1 and B.sub.2 display both antiviral and antimicrobial activity, while component BU-4224V A has antimicrobial activity and component BU-4224V C has antiviral activity.

Antiviral antibiotic BU-4224V

Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

Antiviral antibiotic BU-3889V

The present invention provides BU-4641V of the formula: ##STR1## This invention also provides a biologically pure culture of BU-4641V producing Arthrinium sp. FA1744. Another aspect of the invention provides a process for preparing BU-4641V. Yet further aspect of the present invention provides a method for treating mammalian tumors and bacterial or viral infections.

BU-4641V, an antibacterial, antiviral and antitumor antibiotic

Disclosed is a novel compound, designated BU-4514N, which is produced by cultivation of a novel strain of Microtetraspora, designated species T689-92. The novel compound possesses antibacterial and neuritogenic properties.

Compound produced by a strain of microtetraspora having antibacterial

There is provided a new antiviral antibiotic designated herein as BU-4344V which is produced by fermentation of a BU-4344V-producing strain of a new microorganism, Actinomadura parvosata subsp. kistnae ATCC No. 55076. Antibiotic BU-4344V is recovered and purified from the fermentation broth by use of extraction, chromatography, and crystallization techniques. BU-4344V has been found to have some antibacterial activity and inhibits the growth of viruses, including influenza virus type A.

Antiviral antibiotic BU-4344V

Process for preparing antiviral antibiotic BU-3889V

There is disclosed an antibiotic complex designated as BU-2231 V which is produced by fermentation of a BU-2231-producing strain of Streptoalloteichus hindustanus, ATCC 31158. Complex BU-2231 V is recovered and purified from the fermentation broth by use of ion exchange chromatography techniques. Structural analysis shows that the complex is a mixture of components which are .gamma.-homopolymers of D-.alpha.,.gamma.-diaminobutyric acid having an average molecular weight of from about 5,100 to about 5,200. BU-2231 V has been found to be effective to inhibit growth of various Gram-positive and Gram-negative bacteria and of the herpes simplex virus.

Antiviral antibiotic complex

Addition of certain amine precursor compounds to the culture medium during fermentation of a tallysomycin-producing strain of Streptoalloteichus hindustanus results in production of new tallysomycin derivatives having advantageous antimicrobial and antitumor properties.

Fermentation process for producing tallysomycin compounds

Tallysomycin compounds

Growing community of inventors

Yokohama, Japan

Osamu Tenmyo